CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines

Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

17-Apr-2024 - CureVac N.V. and The University of Texas MD Anderson Cancer Center announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines. The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, ...

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

CureVac to receive an upfront payment of $50 million and an equity investment of €45 million

19-Oct-2017 - Eli Lilly and Company and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology ...

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

22-Sep-2014 - Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, today jointly announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac’s CV9202, a novel investigational therapeutic mRNA vaccine in early ...

CureVac Presents Results of a Phase I/IIa Trial in Non-Small Cell Lung Cancer (NSCLC) with CV9201

09-Nov-2011 - CureVac GmbH presented the results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) with CV9201, an mRNA-based cancer vaccine, in patients with NSCLC stage IIIB/IV after first-line chemo-radiotherapy or chemotherapy, respectively. The trial strived to assess safety and toxicity of ...